Mining the National Cancer Institute's tumor-screening database: Identification of compounds with similar cellular activities

Journal of Medicinal Chemistry

Volumn 45, Issue 4, 2002, Pages 818-840

  Rabow, Alfred A ^a   Shoemaker, Robert H ^b   Sausville, Edward A ^b   Covell, David G ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BISANTRENE; BLEOMYCIN DERIVATIVE; CHELATING AGENT; COLCHICINE DERIVATIVE; CORDYCEPIN; CYTIDINE TRIPHOSPHATE; DEFEROXAMINE; DIHYDROFOLATE REDUCTASE INHIBITOR; DNA TOPOISOMERASE INHIBITOR; FOLIC ACID ANTAGONIST; GUANAZOLE; HYDROXYUREA; INTERCALATING AGENT; MERCAPTOPURINE; METHOTREXATE DERIVATIVE; MYCOPHENOLIC ACID; PODOPHYLLOTOXIN DERIVATIVE; PURINE DERIVATIVE; PYRIMETHAMINE; PYRIMIDINE DERIVATIVE; STILBENE DERIVATIVE; TAXANE DERIVATIVE; TIAZOFURIN; TIOGUANINE; UNINDEXED DRUG; URIDINE PHOSPHATE;

ARTICLE; CANCER SCREENING; CELL CYCLE; CLUSTER ANALYSIS; DATA ANALYSIS; DATA BASE; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME REGULATION; EVALUATION; HUMAN; HUMAN CELL; INTERNET; MEMBRANE STRUCTURE; MEMBRANE TRANSPORT; MITOSIS; NUCLEIC ACID SYNTHESIS; SCORING SYSTEM; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL CYCLE; CELL MEMBRANE; CLUSTER ANALYSIS; DATABASES, FACTUAL; ENZYME INHIBITORS; HUMANS; INTERNET; NATIONAL INSTITUTES OF HEALTH (U.S.); NUCLEIC ACIDS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHOTRANSFERASES; TUMOR CELLS, CULTURED; UNITED STATES;

EID: 0037075063     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010385b     Document Type: Article

References (115)

1. Integrating information technology and drug discovery processes
2. Cluster analysis and display of genome-wide expression patterns
3. An information-intensive approach to the molecular pharmacology of cancer
4. Neural computing in cancer drug development: Predicting mechanism of action
5. Application of high-throughput screening techniques to drug discovery
6. High-throughput and ultrahigh-throughput screening: Solution- and cell-based approaches
7. Combinatorial chemistry as a tool for drug discovery
8. High-throughput screening of enzyme libraries
9. Gene expression profiling: Monitoring transcription and translation products using DNA microarrays and proteomics
10. A gene expression database for the molecular pharmacology of cancer
11. Automated extraction of information in molecular biology
12. Gene expression informatics-it's all in your mine
13. Expression profiling using cDNA microarrays
14. Gene expression data analysis
15. Molecular classification of cutaneous malignant melanoma by gene expression profiling
16. Genomic views of the immune system
17. Interpreting patterns of gene expression with self-organizing maps: Methods and application to hematopoietic differentiation
18. Molecular modeling and drug design
19. Systematic determination of genetic network architecture
20. Visualization of data
21. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays
22. Knowledge-based analysis of microarray gene expression data by using support vector machines
23. Analysis of Gene expression data using self-organizing maps
24. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
25. Feasibility of a high flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
26. The NCI in vitro anticancer drug discovery screen
27. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen
28. Mining the anticancer activity database generated by the U. S. National Cancer Institute's drug discovery program using statistical and artifical intelligence techniques
29. Mining the National Cancer Institute anticancer drug discovery database: Cluster analysis of ellipticine analogues with p53-inverse and central nervous system-selective patterns of activity
30. Mining the NCI anticancer drug discovery databases: Genetic function approximation for the QSAR study of anticancer ellipticine analouges
31. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
32. Characterization of anticancer agents by their growth-inhibitory activity and relationships to mechanism of action and structure
33. On the constructive role of noise in spatial systems
34. Using linear algebra for intelligent information retrieval
35. Use of Kohonen self-organizing maps to study the mechanism of action of chemotherapeutic agents
36. Neural network techniques for informatics of cancer drug discovery
37. Novel software tools for chemical diversity
38. On characterization of chemical structure
39. Molecular identification number for substructure searches
40. Measuring cluster similarity across methods: Sample size estimation for survival outcomes in cluster-randomized studies with small cluster sizes. Cubic clustering criterion
41. Bootstrap confidence intervals for adaptive cluster sampling
42. Comparison of survival between two groups using software SAS, S-PLUS and STATISTICA
43. Measuring cluster similarity across methods
44. Ploidy regulation of gene expression
45. Status of the NCI preclinical antitumor drug discovery screen
46. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute
47. Discrimination techniques applied to the NCI in vitro antitumor drug screen: Predicting biochemical mechanism of action
48. Metabolic basis for the actions of analogues of purines and pyrimidines
49. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation
50. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
51. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin
52. Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells
53. Studies on the mechanism of action of 1-b-D-arabinofuranosyl-5-azacytosine (fazarabine) in mammalian lymphoblasts
54. Actinomycin D as a novel SH2 domain ligand inhibits Shc/Grb2 interaction in B104-1-1 (neu*-transformed NIH3T3) and SAA (hEGFR-overexpressed NIH3T3) cells
55. Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells
56. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity
57. Type 2A protein phosphatase, the complex regulator of numerous signaling pathways
58. Effect of topoisomerase poisoning by antitumor drugs VM 26, fostriecin and camptothecin on DNA repair replication by mammalian cell extracts
59. Cytostatin, an inhibitor of cell adhesion to extracellular matrix, selectively inhibits protein phosphatase 2A
60. Current status and recent developments in anthracenone antipsoriatics
61. Histamine increases [Ca(2+)](in) and activates Ca-K and nonselective cation currents in cultured human capillary endothelial cells
62. Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: Molecular determinants of selective binding to the inactivated channels
63. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole
64. Polarized expression of Ca2+ pumps in pancreatic and salivary gland cells. Role in initiation and propagation of [Ca2+]i waves
65. The rubella virus E1 glycoprotein is arrested in a novel post-ER, pre-Golgi compartment
66. Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells
67. Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin
68. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin
69. New antiactin drugs in the study of the organization and function of the actin cytoskeleton
70. The actin cytoskeleton is required for the trafficking of the b cell antigen receptor to the late endosomes
71. Activation of store-mediated calcium entry by secretion-like coupling between the inositol 1,4,5-trisphosphate receptor type II and human transient receptor potential (hTrp1) channels in human platelets
72. Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release
73. Down-regulation of protein kinase C by parathyroid hormone and mezerein differentially modulates cAMP production and phosphate transport in opossum kidney cells
74. Mechanism of antitumor action of PKC activator, gnidimacrin
75. Total synthesis and stereochemistry of cytoblastin
76. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
77. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis
78. Inhibition of phospholipase C and protein kinase C by alkylphosphocholines
79. Selective accumulation of the endoplasmic reticulum-golgi intermediate compartment induced by the antitumor drug KRN5500
80. Biphasic effect of protein kinase C activators on spontaneous and glucocorticoid-induced apoptosis in primary mouse thymocytes
81. The transient increase of tight junction permeability induced by bryostatin 1 correlates with rapid downregulation Of protein kinase C-a
82. Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase
83. Inhibition of basophil histamine release by tyrosine kinase and phosphatidylinositol 3-kinase inhibitors
84. Induction of apoptosis by ursolic acid through activation of caspases and down-regulation of c-IAPs in human prostate epithelial cells
85. Adenosine triphosphate induces inhibition of Na(+) absorption in mouse endometrial epithelium: A Ca(2+)-dependent mechanism
86. Evidence for a direct correlation between c-Jun NH2 terminal kinase 1 activation, cyclin D2 expression, and G(1)/S phase transition in the murine hybridoma 7TD1 cells
87. Wortmannin inhibition of forskolin-stimulated chloride secretion by T84 cells
88. Forskolin and phorbol ester have opposite effects on the expression of mucin-associated sialyl-Lewis(a) in pancreatic cancer cells
89. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt
90. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation
91. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4
92. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells
93. Mode of action of the anticancer quassinoids-inhibition of the plasma membrane NADH oxidase
94. Thapsigargin induces apoptosis in cultured human aortic smooth muscle cells
95. Trichothecene mycotoxins trigger a ribotoxic stress response that activates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase and induces apoptosis
96. Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity
97. Expression of immediate early gene pip92 during anisomycin-induced cell death is mediated by the JNK- and p38-dependent activation of Elk1
98. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
99. Distinctive gene expression patters in human mammary epithelian cells and creast cancers
100. Molecular portraits of human breast tumours
101. Systematic variation in gene expression patterns in human cancer cell lines
102. Induction by 5-aza-2′-deoxycytidine, an inhibitor of DNA methylation of Leantigen, apoptosis and differentiation in human lung cancer cells
103. Mechanism of the induction of the differentiation of HL-60 cells by antifolates